NVCT

NuvectisC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

25%

Probability

Target price

$14.00

+47.2% vs current

Most likely

Base case

45%

Probability

Target price

$7.50

-21.1% vs current

B-

Bear case

30%

Probability

Target price

$4.50

-52.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-04

AI commentary

This remains a cautious T+1 monitoring update, not a clean post-earnings read: as of May 4, 2026, the provided evidence does not confirm a company Q1 2026 earnings release, shareholder letter, earnings 8-K, or 10-Q, so earnings surprise data, guidance revision, analyst target changes, and post-print price reaction are unavailable. Coverage is thin, recent news flow is sparse, and the thesis still hinges more on future NXP900 data and funding durability than on any newly verified earnings signal.

RankAlpha Sentiment Codex - 2026-05-04

Open post-earnings memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-05-04catalystQ1 2026 earnings packet remains unconfirmed, leaving a near-term information gapHigh impact

As of May 4, 2026, no newer Nuvectis 10-Q or earnings 8-K was confirmed in the available packet, so there is no verified Q1 2026 surprise, guidance, or post-print market-reaction signal. The last confirmed company financial update remains the February 11, 2026 FY2025 earnings 8-K, which said cash could support multiple NXP900 Phase 1b milestones and extend well into the second half of 2027 [#8-K-2026-02-11].

2026-12-31catalystNXP900 Phase 1b data updates are the main re-rating path in 2026High impact

Nuvectis' February 11, 2026 FY2025 update said the Phase 1b monotherapy study of NXP900 in molecularly and histologically defined tumors and the NXP900 plus osimertinib study in EGFR-mutated NSCLC were enrolling patients, while an NXP900 plus lorlatinib study in ALK-positive NSCLC was pending commencement. That makes trial execution and any 2026 Phase 1b data updates the clearest potential re-rating path [#8-K-2026-02-11].

2027-09-30catalystRunway looks adequate for current milestones, but financing overhang is deferred rather than removedHigh impact

The 10-K says currently available cash as of December 31, 2025 is sufficient for planned operations for greater than 12 months, but also says additional capital will be needed to complete clinical development; the FY2025 earnings press release reported $31.6 million of cash as of December 31, 2025 and framed that position as carrying the company through multiple Phase 1b milestones and well into H2 2027 [#10-K-2026-02-11] [#8-K-2026-02-11].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-04 • Updated nightlySource: Internal modelMethodology